Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling

Falk W. Lohoff, Gregory Carr, Bethany Brookshire, Thomas N. Ferraro, Irwin Lucki

Research output: Contribution to journalArticle

Abstract

The vesicular monoamine transporter is involved in presynaptic catecholamine storage and neurotransmission. Two isoforms of the transporter exist, VMAT1 and VMAT2, and both are expressed in the brain, though VMAT2 expression is more robust and has been more widely studied. In this study we investigated the role of VMAT1 KO on markers of dopaminergic function and neurotransmission, and dopamine-related behaviors. Null-mutant VMAT1 mice were studied behaviorally using the tail suspension test, elevated zero maze and locomotor activity assessments. Tissue monoamines were measured both ex vivo and by using in vivo microdialysis. Protein expression of tyrosine hydroxylase and D2 dopamine receptors was measured using western blot analysis. Results show that VMAT1 KO mice have decreased dopamine levels in the frontal cortex, increased postsynaptic D2 expression, and lower frontal cortex tyrosine hydroxylase expression compared to WT mice. VMAT1 KO mice also show an exaggerated behavioral locomotor response to acute amphetamine treatment. We conclude that dopaminergic signaling is robustly altered in the frontal cortex of VMAT1 null-mutant mice and suggest that VMAT1 may be relevant to the pathogenesis and/or treatment of psychiatric illnesses including schizophrenia and bipolar disease.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalBrain research
Volume1712
DOIs
StatePublished - Jun 1 2019

Fingerprint

Vesicular Monoamine Transport Proteins
Dopamine
Frontal Lobe
Genes
Tyrosine 3-Monooxygenase
Synaptic Transmission
Hindlimb Suspension
Dopamine D2 Receptors
Microdialysis
Amphetamine
Locomotion
Catecholamines
Psychiatry
Schizophrenia
Protein Isoforms
Western Blotting
Brain
Therapeutics
Proteins

Keywords

  • Addiction
  • Bipolar disorder
  • DAT
  • Dopamine
  • Schizophrenia
  • SLC18A1
  • VMAT2

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling. / Lohoff, Falk W.; Carr, Gregory; Brookshire, Bethany; Ferraro, Thomas N.; Lucki, Irwin.

In: Brain research, Vol. 1712, 01.06.2019, p. 151-157.

Research output: Contribution to journalArticle

Lohoff, Falk W. ; Carr, Gregory ; Brookshire, Bethany ; Ferraro, Thomas N. ; Lucki, Irwin. / Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling. In: Brain research. 2019 ; Vol. 1712. pp. 151-157.
@article{f6c9445788224ea09d34e4ffe8746cf5,
title = "Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling",
abstract = "The vesicular monoamine transporter is involved in presynaptic catecholamine storage and neurotransmission. Two isoforms of the transporter exist, VMAT1 and VMAT2, and both are expressed in the brain, though VMAT2 expression is more robust and has been more widely studied. In this study we investigated the role of VMAT1 KO on markers of dopaminergic function and neurotransmission, and dopamine-related behaviors. Null-mutant VMAT1 mice were studied behaviorally using the tail suspension test, elevated zero maze and locomotor activity assessments. Tissue monoamines were measured both ex vivo and by using in vivo microdialysis. Protein expression of tyrosine hydroxylase and D2 dopamine receptors was measured using western blot analysis. Results show that VMAT1 KO mice have decreased dopamine levels in the frontal cortex, increased postsynaptic D2 expression, and lower frontal cortex tyrosine hydroxylase expression compared to WT mice. VMAT1 KO mice also show an exaggerated behavioral locomotor response to acute amphetamine treatment. We conclude that dopaminergic signaling is robustly altered in the frontal cortex of VMAT1 null-mutant mice and suggest that VMAT1 may be relevant to the pathogenesis and/or treatment of psychiatric illnesses including schizophrenia and bipolar disease.",
keywords = "Addiction, Bipolar disorder, DAT, Dopamine, Schizophrenia, SLC18A1, VMAT2",
author = "Lohoff, {Falk W.} and Gregory Carr and Bethany Brookshire and Ferraro, {Thomas N.} and Irwin Lucki",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.brainres.2019.01.029",
language = "English (US)",
volume = "1712",
pages = "151--157",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling

AU - Lohoff, Falk W.

AU - Carr, Gregory

AU - Brookshire, Bethany

AU - Ferraro, Thomas N.

AU - Lucki, Irwin

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The vesicular monoamine transporter is involved in presynaptic catecholamine storage and neurotransmission. Two isoforms of the transporter exist, VMAT1 and VMAT2, and both are expressed in the brain, though VMAT2 expression is more robust and has been more widely studied. In this study we investigated the role of VMAT1 KO on markers of dopaminergic function and neurotransmission, and dopamine-related behaviors. Null-mutant VMAT1 mice were studied behaviorally using the tail suspension test, elevated zero maze and locomotor activity assessments. Tissue monoamines were measured both ex vivo and by using in vivo microdialysis. Protein expression of tyrosine hydroxylase and D2 dopamine receptors was measured using western blot analysis. Results show that VMAT1 KO mice have decreased dopamine levels in the frontal cortex, increased postsynaptic D2 expression, and lower frontal cortex tyrosine hydroxylase expression compared to WT mice. VMAT1 KO mice also show an exaggerated behavioral locomotor response to acute amphetamine treatment. We conclude that dopaminergic signaling is robustly altered in the frontal cortex of VMAT1 null-mutant mice and suggest that VMAT1 may be relevant to the pathogenesis and/or treatment of psychiatric illnesses including schizophrenia and bipolar disease.

AB - The vesicular monoamine transporter is involved in presynaptic catecholamine storage and neurotransmission. Two isoforms of the transporter exist, VMAT1 and VMAT2, and both are expressed in the brain, though VMAT2 expression is more robust and has been more widely studied. In this study we investigated the role of VMAT1 KO on markers of dopaminergic function and neurotransmission, and dopamine-related behaviors. Null-mutant VMAT1 mice were studied behaviorally using the tail suspension test, elevated zero maze and locomotor activity assessments. Tissue monoamines were measured both ex vivo and by using in vivo microdialysis. Protein expression of tyrosine hydroxylase and D2 dopamine receptors was measured using western blot analysis. Results show that VMAT1 KO mice have decreased dopamine levels in the frontal cortex, increased postsynaptic D2 expression, and lower frontal cortex tyrosine hydroxylase expression compared to WT mice. VMAT1 KO mice also show an exaggerated behavioral locomotor response to acute amphetamine treatment. We conclude that dopaminergic signaling is robustly altered in the frontal cortex of VMAT1 null-mutant mice and suggest that VMAT1 may be relevant to the pathogenesis and/or treatment of psychiatric illnesses including schizophrenia and bipolar disease.

KW - Addiction

KW - Bipolar disorder

KW - DAT

KW - Dopamine

KW - Schizophrenia

KW - SLC18A1

KW - VMAT2

UR - http://www.scopus.com/inward/record.url?scp=85061658226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061658226&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2019.01.029

DO - 10.1016/j.brainres.2019.01.029

M3 - Article

C2 - 30685272

AN - SCOPUS:85061658226

VL - 1712

SP - 151

EP - 157

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -